{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:20:17Z","timestamp":1795044017663,"version":"4.10.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01322-y","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:39Z","timestamp":1792106559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Patient-Centric Formulation Compass: A Proposed Bottom-Up Framework to Translate Population Insights into Product Design"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7919-5319","authenticated-orcid":false,"given":"Domagoj","family":"Segregur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7591-0814","authenticated-orcid":false,"given":"Pascal","family":"Somville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6156-063X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Mantanus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8136-5616","authenticated-orcid":false,"given":"Talia","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1322_CR1","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.xphs.2023.01.029","volume":"112","author":"M Algorri","year":"2023","unstructured":"Algorri M, Cauchon NS, Christian T, O\u2019Connell C, Vaidya P. Patient-centric product development: a summary of select regulatory CMC and device considerations. J Pharm Sci. 2023;112:922\u201336. https:\/\/doi.org\/10.1016\/j.xphs.2023.01.029.","journal-title":"J Pharm Sci"},{"key":"1322_CR2","volume-title":"People-centred health care: a policy framework","author":"World Health Organization Regional Office for the Western Pacific","year":"2007","unstructured":"World Health Organization Regional Office for the Western Pacific. People-centred health care: a policy framework. Manila: World Health Organization, Western Pacific Region; 2007."},{"key":"1322_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/bmjinnov-2016-000157","volume":"3","author":"G Yeoman","year":"2017","unstructured":"Yeoman G, Furlong P, Seres M, Binder H, Chung H, Garzya V, et al. Defining patient centricity with patients for patients and caregivers: a collaborative endeavour. BMJ Innov. 2017;3:76\u201383. https:\/\/doi.org\/10.1136\/bmjinnov-2016-000157.","journal-title":"BMJ Innov"},{"key":"1322_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11095-019-2616-5","volume":"36","author":"MD Burke","year":"2019","unstructured":"Burke MD, Keeney M, Kleinberg R, Burlage R. Challenges and opportunities for patient centric drug product design: industry perspectives. Pharm Res. 2019;36:85. https:\/\/doi.org\/10.1007\/s11095-019-2616-5.","journal-title":"Pharm Res"},{"key":"1322_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1208\/s12248-016-9938-6","volume":"18","author":"S Stegemann","year":"2016","unstructured":"Stegemann S, Ternik RL, Onder G, Khan MA, van Riet-Nales DA. Defining patient centric pharmaceutical drug product design. AAPS J. 2016;18:1047\u201355. https:\/\/doi.org\/10.1208\/s12248-016-9938-6.","journal-title":"AAPS J"},{"key":"1322_CR6","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1111\/bcp.14388","volume":"86","author":"C Timpe","year":"2020","unstructured":"Timpe C, Stegemann S, Barrett A, Mujumdar S. Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol. 2020;86:2020\u20137. https:\/\/doi.org\/10.1111\/bcp.14388.","journal-title":"Br J Clin Pharmacol"},{"key":"1322_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrd3501","volume":"10","author":"HG Eichler","year":"2011","unstructured":"Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy-effectiveness gap: a regulator\u2019s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495\u2013506. https:\/\/doi.org\/10.1038\/nrd3501.","journal-title":"Nat Rev Drug Discov"},{"key":"1322_CR8","unstructured":"U.S. Food and Drug Administration. FDARA implementation guidance for pediatric studies of molecularly targeted oncology drugs: amendments to sec. 505B of the FD&C act. 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fdara-implementation-guidance-pediatric-studies-molecularly-targeted-oncology-drugs-amendments-sec. Accessed 9 Dec 2025."},{"key":"1322_CR9","unstructured":"U.S. Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 9 Dec 2025."},{"key":"1322_CR10","unstructured":"U.S. Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and food and drug administration staff. 2017. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-real-world-evidence-support-regulatory-decision-making-medical-devices. Accessed 9 Dec 2025."},{"key":"1322_CR11","unstructured":"U.S. Food and Drug Administration. Applying human factors and usability engineering to medical devices: guidance for industry and Food and Drug Administration staff. 2016. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applying-human-factors-and-usability-engineering-medical-devices. Accessed 9 Dec 2025."},{"key":"1322_CR12","unstructured":"European Medicines Agency. Reflection paper on the pharmaceutical development of medicines for use in the older population. 2017. https:\/\/www.ema.europa.eu\/en\/pharmaceutical-development-medicines-use-older-population-scientific-guideline. Accessed 9 Dec 2025."},{"key":"1322_CR13","unstructured":"European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. 2013. https:\/\/www.ema.europa.eu\/en\/pharmaceutical-development-medicines-paediatric-use-scientific-guideline. Accessed 9 Dec 2025."},{"key":"1322_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijpharm.2014.03.057","volume":"469","author":"P Kozarewicz","year":"2014","unstructured":"Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. Int J Pharm. 2014;469:245\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.03.057.","journal-title":"Int J Pharm"},{"key":"1322_CR15","unstructured":"International Conference on Harmonisation (ICH) Working Group. Pharmaceutical development Q8(R2): ICH harmonised tripartite guideline. 2009. https:\/\/database.ich.org\/sites\/default\/files\/Q8_R2_Guideline.pdf. Accessed 9 Dec 2025."},{"key":"1322_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijpharm.2016.01.051","volume":"512","author":"S Stegemann","year":"2016","unstructured":"Stegemann S. Towards better understanding of patient centric drug product development in an increasingly older patient population. Int J Pharm. 2016;512:334\u201342. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.01.051.","journal-title":"Int J Pharm"},{"key":"1322_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bcp.14511","volume":"86","author":"S Stegemann","year":"2020","unstructured":"Stegemann S, van Riet-Nales D, de Boer A. Demographics in the 2020s-Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life. Br J Clin Pharmacol. 2020;86:1899\u2013903. https:\/\/doi.org\/10.1111\/bcp.14511.","journal-title":"Br J Clin Pharmacol"},{"key":"1322_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2023.04.017","volume":"188","author":"S Stegemann","year":"2023","unstructured":"Stegemann S, Klingmann V, Reidemeister S, Breitkreutz J. Patient-centric drug product development: acceptability across patient populations - Science and evidence. Eur J Pharm Biopharm. 2023;188:1\u20135. https:\/\/doi.org\/10.1016\/j.ejpb.2023.04.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"1322_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13030213","author":"A Adeogun","year":"2025","unstructured":"Adeogun A, Faezipour M. Patient-centric paradigm: a systems thinking approach to enhance healthcare. Healthcare (Basel). 2025. https:\/\/doi.org\/10.3390\/healthcare13030213.","journal-title":"Healthcare (Basel)"},{"key":"1322_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17425247.2018.1472571","volume":"15","author":"S Stegemann","year":"2018","unstructured":"Stegemann S. Patient centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness. Expert Opin Drug Deliv. 2018;15:619\u201327. https:\/\/doi.org\/10.1080\/17425247.2018.1472571.","journal-title":"Expert Opin Drug Deliv"},{"key":"1322_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejpb.2022.06.006","volume":"177","author":"S Stegemann","year":"2022","unstructured":"Stegemann S, Sheehan L, Rossi A, Barrett A, Paudel A, Crean A, et al. Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes - A proposed roadmap. Eur J Pharm Biopharm. 2022;177:81\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2022.06.006.","journal-title":"Eur J Pharm Biopharm"},{"key":"1322_CR22","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1016\/j.xphs.2019.06.021","volume":"108","author":"D Segregur","year":"2019","unstructured":"Segregur D, Flanagan T, Mann J, Moir A, Karlsson EM, Hoch M, et al. Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes. J Pharm Sci. 2019;108:3461\u201377. https:\/\/doi.org\/10.1016\/j.xphs.2019.06.021.","journal-title":"J Pharm Sci"},{"key":"1322_CR23","unstructured":"U.S. Food and Drug Administration. Evaluation of gastric pH-Dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications guidance for industry: guidance for industry. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis. Accessed 9 Dec 2025."},{"key":"1322_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.14503\/THIJ-16-5903","volume":"43","author":"HL Fred","year":"2016","unstructured":"Fred HL. When patient-centered care isn\u2019t. Texas Heart Inst J. 2016;43:281\u20132. https:\/\/doi.org\/10.14503\/THIJ-16-5903.","journal-title":"Texas Heart Inst J."},{"key":"1322_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1574884716666210427115820","volume":"17","author":"T van Iersel","year":"2022","unstructured":"van Iersel T, Courville J, van Doorne C, Koster RA, Fawcett C. The patient motivation pyramid and patient-centricity in early clinical development. Curr Rev Clin Exp Pharmacol. 2022;17:8\u201317. https:\/\/doi.org\/10.2174\/1574884716666210427115820.","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"1322_CR26","doi-asserted-by":"publisher","first-page":"1237124","DOI":"10.3389\/frai.2023.1237124","volume":"6","author":"P Karmalkar","year":"2023","unstructured":"Karmalkar P, Gurulingappa H, Spies E, Flynn JA. Artificial intelligence-driven approach for patient-focused drug development. Front Artif Intell. 2023;6:1237124. https:\/\/doi.org\/10.3389\/frai.2023.1237124.","journal-title":"Front Artif Intell"},{"key":"1322_CR27","doi-asserted-by":"publisher","unstructured":"Manteghi R, Veas E, Segregur D. Customizable categorization of documents in evidence-based research for bio pharmaceutics. 2023. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.10611196.","DOI":"10.5281\/zenodo.10611196"},{"key":"1322_CR28","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.3390\/electronics13234712","volume":"13","author":"M Gozzi","year":"2024","unstructured":"Gozzi M, Di Maio F. Comparative analysis of prompt strategies for large language models: single-Task vs. Multitask Prompts Electron. 2024;13:4712. https:\/\/doi.org\/10.3390\/electronics13234712.","journal-title":"Multitask Prompts Electron."},{"key":"1322_CR29","doi-asserted-by":"publisher","unstructured":"Long DX, Dinh D, Nguyen NH, Kawaguchi K, Chen NF, Joty S, Kan MY. What makes a good natural language prompt? arXiv. 2025. https:\/\/doi.org\/10.48550\/arXiv.2506.06950.","DOI":"10.48550\/arXiv.2506.06950"},{"key":"1322_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1208\/s12248-020-00470-z","volume":"22","author":"A Selen","year":"2020","unstructured":"Selen A, M\u00fcllertz A, Kesisoglou F, Ho RJY, Cook JA, Dickinson PA, et al. Integrated multi-stakeholder systems thinking strategy: decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to optimize clinical performance of drug products. AAPS J. 2020;22:97. https:\/\/doi.org\/10.1208\/s12248-020-00470-z.","journal-title":"AAPS J"},{"key":"1322_CR31","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1016\/j.xphs.2016.07.024","volume":"105","author":"PA Dickinson","year":"2016","unstructured":"Dickinson PA, Kesisoglou F, Flanagan T, Martinez MN, Mistry HB, Crison JR, et al. Optimizing clinical drug product performance: applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM scoring grid. J Pharm Sci. 2016;105:3243\u201355. https:\/\/doi.org\/10.1016\/j.xphs.2016.07.024.","journal-title":"J Pharm Sci"},{"key":"1322_CR32","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/jps.24162","volume":"103","author":"A Selen","year":"2014","unstructured":"Selen A, Dickinson PA, M\u00fcllertz A, Crison JR, Mistry HB, Crua\u00f1es MT, et al. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. J Pharm Sci. 2014;103:3377\u201397. https:\/\/doi.org\/10.1002\/jps.24162.","journal-title":"J Pharm Sci"},{"key":"1322_CR33","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1021\/acs.cgd.5b01417","volume":"12","author":"\u00d6 Almarsson","year":"2015","unstructured":"Almarsson \u00d6, Vadas EB. Molecules, materials, medicines (M3): linking molecules to medicines through pharmaceutical material science. Cryst Growth Des. 2015;12:5645\u20137. https:\/\/doi.org\/10.1021\/acs.cgd.5b01417.","journal-title":"Cryst Growth Des"},{"key":"1322_CR34","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.apsb.2021.05.002","volume":"11","author":"Y Shi","year":"2021","unstructured":"Shi Y, Lu A, Wang X, Belhadj Z, Wang J, Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B. 2021;11:2396\u2013415. https:\/\/doi.org\/10.1016\/j.apsb.2021.05.002.","journal-title":"Acta Pharm Sin B"},{"key":"1322_CR35","doi-asserted-by":"publisher","first-page":"e70241","DOI":"10.1111\/cts.70241","volume":"18","author":"P Singh","year":"2025","unstructured":"Singh P, Sverdlov O, Beckman RA, Burden AM. Integrating sustainability pillars into trial design decision-making: results of an international survey. Clin Transl Sci. 2025;18:e70241. https:\/\/doi.org\/10.1111\/cts.70241.","journal-title":"Clin Transl Sci"},{"key":"1322_CR36","unstructured":"Segregur D. PharmSci 360 2025 Poster: Sustainability Considerations in Patient-Centric Formulation Selection. In: PharmSci 360 2025. Poster M1330\u201309\u201360, 2025."},{"key":"1322_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s12325-024-03076-5","volume":"42","author":"M Yang","year":"2025","unstructured":"Yang M, Mittal M, Fendrick AM, Brixner D, Sherman BW, Liu Y, et al. An access-focused patient-centric value assessment framework for medication formulary decision-making in immune-mediated inflammatory diseases. Adv Ther. 2025;42:568\u201378. https:\/\/doi.org\/10.1007\/s12325-024-03076-5.","journal-title":"Adv Ther"},{"key":"1322_CR38","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1161\/CIRCULATIONAHA.114.013135","volume":"130","author":"RM Califf","year":"2014","unstructured":"Califf RM. Patient-centered outcomes composites: a glimpse of the future. Circulation. 2014;130:1223\u20134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013135.","journal-title":"Circulation"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01322-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:14:41Z","timestamp":1795043681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01322-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01322-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of UCB Pharma and may own company stock or stock options.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations\u00a0"}}],"article-number":"170"}}